Most medical regulators including Australia's demand that COVID-19 vaccines be 50 per cent efficacious at a minimum. So what does this mean? And is this number high enough?
Biden to Release More Doses: Virus Update Bloomberg 1/8/2021 Bloomberg News
(Bloomberg) President-elect Joe Biden says he’ll distribute more of the available doses of coronavirus vaccines, as the U.S. surpassed 4,000 daily fatalities for the first time. New York City has 270,000 unused vaccine doses that it’s seeking to administer to residents over age 75, Mayor Bill de Blasio said. Maine broke records for infections and deaths.
London’s mayor declared an emergency as the U.K. reported record fatalities. Germany also reported the most daily deaths since the start of the pandemic.
As the U.K. approved the Moderna Inc. vaccine for emergency use, the European Union secured an extra 300 million doses of the Pfizer Inc.-BioNTech SE shot. Iran banned U.S. and U.K. vaccinations.
Viruses mutate all the time, including the novel coronavirus that’s caused the global pandemic. But a variant that emerged in southeast England in September is causing particular concern, sending the U.K. back into lockdown and prompting many places to halt flights and suspend rail links.
Biden to Release More Doses: Virus Update Bloomberg 1/8/2021 Bloomberg News
(Bloomberg) President-elect Joe Biden says he’ll distribute more of the available doses of coronavirus vaccines, as the U.S. surpassed 4,000 daily fatalities for the first time. New York City has 270,000 unused vaccine doses that it’s seeking to administer to residents over age 75, Mayor Bill de Blasio said. Maine broke records for infections and deaths.
London’s mayor declared an emergency as the U.K. reported record fatalities. Germany also reported the most daily deaths since the start of the pandemic.
As the U.K. approved the Moderna Inc. vaccine for emergency use, the European Union secured an extra 300 million doses of the Pfizer Inc.-BioNTech SE shot. Iran banned U.S. and U.K. vaccinations.
Credit: RedHill Biopharma
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms
Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of treatment at Day 14 in the opaganib-treated arm across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal scale
The opaganib-treated arm demonstrated a greater improvement in reaching room air within 14 days (52.6% vs. 22.2%); greater improvement in reduction to 50% supplemental oxygen by Day 14 (89.5% vs. 66.7%); a higher proportion of patients discharged by Day 14 (73.7% vs. 55.6%) and a greater reduction in the median total oxygen requirement (AUC) over 14 days (68.0% vs. 46.7%)